FAB Pharma, A Biopharma Company Developing Drugs To Treat Severe Bacterial Infections

FAB Pharma announced the completion of a 2.3 million euro round of series A funding led by CDC innovation and co-led by Bioam Gestion. FAB Pharma has acquired assets in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) from Mutabilis S.A. Severe infections caused by MRSA is a growing issue, especially in the hospital where it is one of the main causes of nosocomial infections.